DGXNYSEServices-Medical LaboratoriesFiscal year ends December 31
QUEST DIAGNOSTICS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026
$234.91−0.09 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $26.31B
- P/E (TTM)
- 25.0
- Dividend yield
- –
QUEST DIAGNOSTICS INC revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIS business | $11.31B | $11.03B | $10.79B | $10.60B | $10.27B | $9.91B | $9.61B | $9.28B | $9.08B | $9.02B | $8.98B | $9.02B | 97.8% | +10.1% |
| All other operating segments | $253.00M | $250.00M | $250.00M | $251.00M | $251.00M | $253.00M | $258.00M | $260.00M | $266.00M | $272.00M | $276.00M | $277.00M | 2.2% | +0.8% |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DIS business | $1.92B | $1.87B | $1.83B | $1.82B | $1.75B | $1.67B | $1.63B | $1.57B | $1.56B | $1.55B | $1.55B | $1.44B | +10.0% |
| All other operating segments | $34.00M | $31.00M | $32.00M | $34.00M | $31.00M | $32.00M | $33.00M | $31.00M | $33.00M | $35.00M | $34.00M | $30.00M | +9.7% |
| General corporate activities | -$323.00M | -$294.00M | -$305.00M | -$323.00M | -$301.00M | -$311.00M | -$317.00M | -$350.00M | -$325.00M | -$324.00M | -$319.00M | -$335.00M | +7.3% |
By product or service
By region
From the segment and revenue-disaggregation notes of Quest Diagnostics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.